Mechanized lipoprotein(a) assay as a marker for coronary artery disease illustrates the usefulness of high lipoprotein(a) levels

Clinica Chimica Acta

Volumn 274, Issue 1, 1998, Pages 1-13

  Hobbs, Gregory A ^a   Kaplan, Irina V ^b   Levinson, Stanley S ^b,c  

^a The Lab Inc   (United States)

^b University of Louisville School of Medicine   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apolipoproteins; Atherogenicity; Lipoprotein(a); Mechanized

Indexed keywords

LIPOPROTEIN A; MARKER;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNONEPHELOMETRY; INTERMETHOD COMPARISON; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; POLYSORBATES; REAGENT KITS, DIAGNOSTIC; ROC CURVE; SPECIMEN HANDLING;

EID: 0032496670     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00038-2     Document Type: Article

References (29)

1. [1] Grinstead GF, Ellefson RD. Heterogeneity of Lp(a) and apolipoprotein (a). Clin Chem 1988;34:1036-40.
2. [2] Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
3. [3] Fortmann SP, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle. Editorial. Circulation 1997;95:295-6.
4. [4] Grainger DJ, Kirshenlohr HL, Metcalfe JC et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-8.
5. [5] Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991;32:317-27.
6. [6] Reblin T, Meyer N, Labeur C et al. Extraction of lipoprotein(a) from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995;113:179-88.
7. [7] Gurewich V, Mittleman M. Lipoprotein (a) in coronary heart disease: is it a risk factor after all? Editorial. J Am Med Assoc 1994;271:1025-2026.
8. [8] Gillery P, Arthuis P, Cuperlier C et al. Rate nephelometric assay of serum lipoprotein(a). Clin Chem 1993;39:503-8.
9. [9] Molinari EA, Pichler P, Grillhofer H et al. Immunoturbidimetric determination of lipoprotein(a): improvement in measurement of turbid and triglyceride-rich samples. Clin Chim Acta 1995;235:59-69.
10. [10] Contois JH, Lammi-Keefe CJ, Vogel S et al. Plasma lipoprotein(a) distribution in the Framingham offspring study as determined with a commercially available immunoturbidimetric assay. Clin Chim Acta 1996;253:21-35.
11. [11] Taddei-Peters WC, Butman BT, Jones GR et al. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem 1993;39:1382-9.
12. [12] Taddei-Peters WC, Jürgens G, Wilklund O et al. ELISA quantitation of Lp(a) concentration demonstrates that Lp(a) is an important risk factor in cerebro- and cardiovascular disease. (abstract). Clin Chem 1994;40:1098-9.
13. [13] Jürgens G, Taddei-Peters WC, Költringer P et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8.
14. [14] Levinson SS, Hobbs GA. Optimized automated apolipoprotein A-I assays as markers for coronary artery disease. Arch Pathol Lab Med 1997;121:678-84.
15. [15] Levinson SS, Wagner S. Assay of apolipoprotein B containing lipoproteins for routine use. Arch Pathol Lab Med 1992;116:1350-4.
16. [16] Maciejko JJ, Homes DR, Kottke BA et al. Apolipoprotein AI as a marker of angiographically assessed coronary artery disease. N Engl J Med 1983;309:385-9.
17. [17] Kottke BA, Zinsmeister AR, Holmes Jr. DR et al. Apolipoproteins and coronary artery disease. Mayo Clin Proc 1986;61:313-20.
18. 2+/dextran sulfate in its enzymatic measurement. Clin Chem 1978;24:931-3.
19. [19] Warnick GR, Nguyen T, Albers JJ. Comparison of improved precipitation methods for quantitation of high-density lipoprotein cholesterol. Clin Chem 1985;31:217-22.
20. [20] Harris N, Galpchian V, Rifai N. Three routine methods for measuring high-density lipoprotein cholesterol compared with the reference method. Clin Chem 1996;42:738-43.
21. [21] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. [22] Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay for Lp(a). J Lipid Res 1989;30:651-62.
23. [23] Maciejko JJ, Levinson SS, Markyvech L et al. Evaluation of a new method for assaying APO A I and APO B lipoproteins by rate nephelometry. Clin Chem 1987;11:2065-9.
24. [24] Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
25. [25] Henderson AR. Chemistry with confidence: should clinical chemistry require confidence intervals for analytical and other data. Clin Chem 1993;39:929-34.
26. [26] Beck JR, Schultz K. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986;110:13-20.
27. [27] Guyton JR, Dahlen GH, Patsch W et al. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985;5:565-72.
28. [28] Sgoutas DS, Tuten T. Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a). Clin Chem 1992;38:1873-7.
29. [29] Maher VMG, Brown G, Marcovia SM et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). J Am Med Assoc 1996;274:1771-4.